Published in Nature on February 22, 2007
The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity (2008) 10.55
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet (2009) 9.45
Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis. Nat Genet (2009) 5.93
The IL-1 family: regulators of immunity. Nat Rev Immunol (2010) 4.65
IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest (2008) 4.12
MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS One (2007) 3.96
Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med (2007) 3.68
Skin immune sentinels in health and disease. Nat Rev Immunol (2009) 3.52
Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol (2008) 3.22
Alcohol intake and risk of incident psoriasis in US women: a prospective study. Arch Dermatol (2010) 2.86
Hypertension, antihypertensive medication use, and risk of psoriasis. JAMA Dermatol (2014) 2.85
Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med (2009) 2.68
Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol (2008) 2.20
Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol (2008) 2.19
Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp Med (2015) 2.11
PSORS2 is due to mutations in CARD14. Am J Hum Genet (2012) 2.10
A genomic approach to human autoimmune diseases. Annu Rev Immunol (2010) 2.10
Immunology of psoriasis. Annu Rev Immunol (2014) 2.06
A subpopulation of CD163-positive macrophages is classically activated in psoriasis. J Invest Dermatol (2010) 1.89
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol (2009) 1.89
Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet (2012) 1.88
CD40 and autoimmunity: the dark side of a great activator. Semin Immunol (2009) 1.80
Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. Hum Mol Genet (2011) 1.74
Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep (2007) 1.69
Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med (2008) 1.67
CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. J Clin Invest (2009) 1.65
Cutting edge: A critical functional role for IL-23 in psoriasis. J Immunol (2010) 1.61
Assessment of the psoriatic transcriptome in a large sample: additional regulated genes and comparisons with in vitro models. J Invest Dermatol (2010) 1.61
Psoriasis: what we have learned from mouse models. Nat Rev Rheumatol (2010) 1.61
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol (2013) 1.59
Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest (2012) 1.58
Multiple Loci within the major histocompatibility complex confer risk of psoriasis. PLoS Genet (2009) 1.58
Activator protein 1 (Fos/Jun) functions in inflammatory bone and skin disease. Arthritis Res Ther (2008) 1.54
Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol (2011) 1.50
Angiogenesis drives psoriasis pathogenesis. Int J Exp Pathol (2009) 1.49
CD1a on Langerhans cells controls inflammatory skin disease. Nat Immunol (2016) 1.48
Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol (2011) 1.47
Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris. Br J Dermatol (2015) 1.47
IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol (2012) 1.46
T-helper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol (2008) 1.46
Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med (2009) 1.45
Personal history of gallstones and risk of incident psoriasis and psoriatic arthritis in U.S. women. Br J Dermatol (2015) 1.40
Th17 cells in immunity and autoimmunity. Clin Dev Immunol (2013) 1.40
Psoriasis genetics: breaking the barrier. Trends Genet (2010) 1.38
DNA methylation and gene expression changes in monozygotic twins discordant for psoriasis: identification of epigenetically dysregulated genes. PLoS Genet (2012) 1.35
New insights in the immunologic basis of psoriasis. Semin Cutan Med Surg (2010) 1.29
The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J Clin Invest (2008) 1.27
Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study. Br J Dermatol (2012) 1.26
Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. J Allergy Clin Immunol (2010) 1.25
The Role of MicroRNA in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y) (2010) 1.22
Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol (2013) 1.20
Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol (2008) 1.18
TH17 Cells in Autoimmunity and Immunodeficiency: Protective or Pathogenic? Front Immunol (2012) 1.17
Vitamin D analogs differentially control antimicrobial peptide/"alarmin" expression in psoriasis. PLoS One (2009) 1.17
MiRNA expression in psoriatic skin: reciprocal regulation of hsa-miR-99a and IGF-1R. PLoS One (2011) 1.15
Psoriasis and risk of type 2 diabetes among women and men in the United States: a population-based cohort study. J Invest Dermatol (2011) 1.14
MicroRNAs: control and loss of control in human physiology and disease. World J Surg (2009) 1.12
Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol (2010) 1.10
Development and validation of human psoriatic skin equivalents. Am J Pathol (2008) 1.09
Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis Model Mech (2012) 1.09
Evidence for altered Wnt signaling in psoriatic skin. J Invest Dermatol (2010) 1.08
The psoriasis-associated D10N variant of the adaptor Act1 with impaired regulation by the molecular chaperone hsp90. Nat Immunol (2012) 1.08
Inactivation of FIP200 leads to inflammatory skin disorder, but not tumorigenesis, in conditional knock-out mouse models. J Biol Chem (2008) 1.07
Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci (2010) 1.06
Specific TRPC6 channel activation, a novel approach to stimulate keratinocyte differentiation. J Biol Chem (2008) 1.06
The Role of MicroRNAs in Human Diseases. Avicenna J Med Biotechnol (2010) 1.04
Progress in understanding the immunopathogenesis of psoriasis. Actas Dermosifiliogr (2009) 1.04
Loss of serum response factor in keratinocytes results in hyperproliferative skin disease in mice. J Clin Invest (2009) 1.03
Activation of keratinocyte protein kinase C zeta in psoriasis plaques. J Invest Dermatol (2008) 1.02
Smoking and risk of incident psoriasis among women and men in the United States: a combined analysis. Am J Epidemiol (2012) 1.02
CCN1, a Pro-Inflammatory Factor, Aggravates Psoriasis Skin Lesions by Promoting Keratinocyte Activation. J Invest Dermatol (2015) 1.02
Elucidating glycosaminoglycan-protein-protein interactions using carbohydrate microarray and computational approaches. Proc Natl Acad Sci U S A (2011) 1.00
MicroRNAs in skin and wound healing. Physiol Genomics (2010) 1.00
The ENTH domain protein Clint1 is required for epidermal homeostasis in zebrafish. Development (2009) 1.00
Heterogeneity of inflammatory and cytokine networks in chronic plaque psoriasis. PLoS One (2012) 1.00
A single intradermal injection of IFN-γ induces an inflammatory state in both non-lesional psoriatic and healthy skin. J Invest Dermatol (2012) 1.00
Chronic skin-specific inflammation promotes vascular inflammation and thrombosis. J Invest Dermatol (2012) 0.99
Hypercholesterolemia and risk of incident psoriasis and psoriatic arthritis in US women. Arthritis Rheumatol (2014) 0.98
Novel insights into the role of S100A8/A9 in skin biology. Exp Dermatol (2012) 0.98
NK cells and psoriasis. J Biomed Biotechnol (2011) 0.97
Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab. MAbs (2014) 0.97
Cytokines and the skin barrier. Int J Mol Sci (2013) 0.96
Double anti-angiogenic and anti-inflammatory protein Valpha targeting VEGF-A and TNF-alpha in retinopathy and psoriasis. J Biol Chem (2011) 0.96
Update on the natural history and systemic treatment of psoriasis. Adv Dermatol (2008) 0.96
Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? Trans Am Clin Climatol Assoc (2013) 0.96
IL-17 in psoriasis: implications for therapy and cardiovascular co-morbidities. Cytokine (2013) 0.95
Functional analysis of the RNF114 psoriasis susceptibility gene implicates innate immune responses to double-stranded RNA in disease pathogenesis. Hum Mol Genet (2011) 0.95
T(H)1, T(H)2, and T(H)17 cells instruct monocytes to differentiate into specialized dendritic cell subsets. Blood (2011) 0.95
The immunogenetics of Psoriasis: A comprehensive review. J Autoimmun (2015) 0.95
Grainyhead-like 2 (GRHL2) inhibits keratinocyte differentiation through epigenetic mechanism. Cell Death Dis (2012) 0.94
Toll-like receptors: role in dermatological disease. Mediators Inflamm (2010) 0.93
Plasmacytoid dendritic cells in antiviral immunity and autoimmunity. Sci China Life Sci (2010) 0.93
Platelet-activating factor blockade inhibits the T-helper type 17 cell pathway and suppresses psoriasis-like skin disease in K5.hTGF-β1 transgenic mice. Am J Pathol (2011) 0.92
Keratinocyte apoptosis in epidermal remodeling and clearance of psoriasis induced by UV radiation. J Invest Dermatol (2011) 0.92
Promising new treatments for psoriasis. ScientificWorldJournal (2013) 0.91
Topical delivery of anti-TNFα siRNA and capsaicin via novel lipid-polymer hybrid nanoparticles efficiently inhibits skin inflammation in vivo. J Control Release (2013) 0.91
Regulation of the psoriatic chemokine CCL20 by E3 ligases Trim32 and Piasy in keratinocytes. J Invest Dermatol (2010) 0.89
Serum prolactin levels in psoriasis and its association with disease activity: a case-control study. Indian J Dermatol (2014) 0.89
Loss of epidermal Evi/Wls results in a phenotype resembling psoriasiform dermatitis. J Exp Med (2013) 0.89
Endotoxin augmented antigen-induced Th1 cell trafficking amplifies airway neutrophilic inflammation. J Immunol (2009) 0.89
Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet (2009) 9.45
Frequent mutation of BAP1 in metastasizing uveal melanomas. Science (2010) 7.47
Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med (2012) 6.17
A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet (2008) 5.85
Completing the map of human genetic variation. Nature (2007) 4.38
Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol (2008) 4.18
Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet (2012) 4.13
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med (2004) 4.02
Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med (2007) 3.68
Direct genomic selection. Nat Methods (2005) 3.61
A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet (2003) 3.52
Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics (2003) 3.39
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA (2011) 3.29
Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci (2008) 3.14
AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat Genet (2002) 3.09
Getting under the skin: the immunogenetics of psoriasis. Nat Rev Immunol (2005) 2.83
IL-22-producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol (2009) 2.77
Genome-wide association analysis identifies three psoriasis susceptibility loci. Nat Genet (2010) 2.76
Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res (2011) 2.54
Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A (2005) 2.47
Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol (2010) 2.46
Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages. J Clin Invest (2007) 2.46
Association analyses identify six new psoriasis susceptibility loci in the Chinese population. Nat Genet (2010) 2.41
TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol (2005) 2.29
Genomics: guilt by association. Nature (2007) 2.27
Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet (2013) 2.20
Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol (2008) 2.19
Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep (2011) 2.17
Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A (2005) 2.12
PSORS2 is due to mutations in CARD14. Am J Hum Genet (2012) 2.10
Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol (2010) 2.09
Immunology of psoriasis. Annu Rev Immunol (2014) 2.06
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol (2004) 2.05
Genomic analysis defines a cancer-specific gene expression signature for human squamous cell carcinoma and distinguishes malignant hyperproliferation from benign hyperplasia. J Invest Dermatol (2006) 2.01
Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. Trends Immunol (2004) 1.92
Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol (2008) 1.90
A subpopulation of CD163-positive macrophages is classically activated in psoriasis. J Invest Dermatol (2010) 1.89
Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet (2012) 1.88
Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. J Invest Dermatol (2010) 1.84
Contrasting pathogenesis of atopic dermatitis and psoriasis--part I: clinical and pathologic concepts. J Allergy Clin Immunol (2011) 1.84
Contrasting pathogenesis of atopic dermatitis and psoriasis--part II: immune cell subsets and therapeutic concepts. J Allergy Clin Immunol (2011) 1.77
Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol (2009) 1.76
Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA). PLoS One (2010) 1.75
Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome. Hum Mol Genet (2011) 1.74
A subset of methylated CpG sites differentiate psoriatic from normal skin. J Invest Dermatol (2011) 1.73
Resident and "inflammatory" dendritic cells in human skin. J Invest Dermatol (2008) 1.72
The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol (2012) 1.71
Combining several ordinal measures in clinical studies. Stat Med (2004) 1.71
Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma. Clin Cancer Res (2007) 1.71
The human cutaneous squamous cell carcinoma microenvironment is characterized by increased lymphatic density and enhanced expression of macrophage-derived VEGF-C. J Invest Dermatol (2010) 1.70
Meta-analysis derived (MAD) transcriptome of psoriasis defines the "core" pathogenesis of disease. PLoS One (2012) 1.70
Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol (2012) 1.69
IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis. J Invest Dermatol (2013) 1.65
Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. J Allergy Clin Immunol (2007) 1.60
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol (2013) 1.59
Multiple Loci within the major histocompatibility complex confer risk of psoriasis. PLoS Genet (2009) 1.58
Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol (2012) 1.56
AJC editor's consensus: psoriasis and coronary artery disease. Am J Cardiol (2008) 1.54
Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol (2009) 1.54
Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol (2011) 1.50
Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. J Allergy Clin Immunol (2009) 1.50
Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production. Proc Natl Acad Sci U S A (2009) 1.44
Two novel point mutations in the long-range SHH enhancer in three families with triphalangeal thumb and preaxial polydactyly. Am J Med Genet A (2007) 1.41
Psoriasis genetics: breaking the barrier. Trends Genet (2010) 1.38
Localization of PSORS1 to a haplotype block harboring HLA-C and distinct from corneodesmosin and HCR. Hum Genet (2005) 1.37
New insights into the pathogenesis and genetics of psoriatic arthritis. Nat Clin Pract Rheumatol (2009) 1.35
Human keratinocytes' response to injury upregulates CCL20 and other genes linking innate and adaptive immunity. J Invest Dermatol (2011) 1.30
A novel chimeric lysin shows superiority to mupirocin for skin decolonization of methicillin-resistant and -sensitive Staphylococcus aureus strains. Antimicrob Agents Chemother (2010) 1.29
New insights in the immunologic basis of psoriasis. Semin Cutan Med Surg (2010) 1.29
Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clin Immunol (2004) 1.27
A genetic risk score combining ten psoriasis risk loci improves disease prediction. PLoS One (2011) 1.25
Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. J Allergy Clin Immunol (2010) 1.25
Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated. J Invest Dermatol (2011) 1.24
Novel immunoglobulin superfamily gene cluster, mapping to a region of human chromosome 17q25, linked to psoriasis susceptibility. Hum Genet (2002) 1.24
Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol (2012) 1.23
Resolved psoriasis lesions retain expression of a subset of disease-related genes. J Invest Dermatol (2010) 1.22
Asymmetric lower-limb malformations in individuals with homeobox PITX1 gene mutation. Am J Hum Genet (2008) 1.21
Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. Eur J Cancer (2010) 1.21
Combined use of laser capture microdissection and cDNA microarray analysis identifies locally expressed disease-related genes in focal regions of psoriasis vulgaris skin lesions. J Invest Dermatol (2012) 1.20
Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol (2013) 1.19
Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: Gene regulation and cellular effects. J Invest Dermatol (2006) 1.19
TNF-α downregulates filaggrin and loricrin through c-Jun N-terminal kinase: role for TNF-α antagonists to improve skin barrier. J Invest Dermatol (2011) 1.18
Transcriptional profiling of psoriasis using RNA-seq reveals previously unidentified differentially expressed genes. J Invest Dermatol (2011) 1.15
Human basal cell carcinoma is associated with Foxp3+ T cells in a Th2 dominant microenvironment. J Invest Dermatol (2007) 1.14
Th17 cells and activated dendritic cells are increased in vitiligo lesions. PLoS One (2011) 1.14
Activating killer cell immunoglobulin-like receptor gene KIR2DS1 is associated with psoriatic arthritis. Hum Immunol (2005) 1.14
Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis. J Transl Med (2007) 1.14
A transmission disequilibrium test for general pedigrees that is robust to the presence of random genotyping errors and any number of untyped parents. Eur J Hum Genet (2004) 1.13
Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol (2002) 1.13
Psoriasis patients are enriched for genetic variants that protect against HIV-1 disease. PLoS Genet (2012) 1.10
Novel insight into the agonistic mechanism of alefacept in vivo: differentially expressed genes may serve as biomarkers of response in psoriasis patients. J Immunol (2007) 1.09
Putting together the psoriasis puzzle: an update on developing targeted therapies. Dis Model Mech (2012) 1.09
Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. J Clin Immunol (2009) 1.08
Atopic dermatitis results in intrinsic barrier and immune abnormalities: implications for contact dermatitis. J Allergy Clin Immunol (2012) 1.05